Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study
Open Access
- 30 July 2026
- journal article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (5)
Abstract
Aims: Tafamidis was the first drug approved for transthyretin amyloid cardiomyopathy (ATTR-CM), but contemporary real-world evidence is lacking. Methods and results: This retrospective, multicentre study included ATTR-CM patients enrolled after commercial availability of tafamidis 61 mg in Germany (April 2020 to March 2021), with treatment initiation based on physician clinical judgement. Primary and secondary endpoints were all-cause mortality and the composite of all-cause mortality and/or heart failure (HF) hospitalization, respectively. The cohort comprised 329 patients (median age 80 [76–83] years, 85% male and 8% variant ATTR) and 80% received tafamidis. During a median follow-up of 39 [18–48] months, 21% of patients died and 42% reached the composite endpoint. Tafamidis-treated patients had a 3-year survival of 86% and an event-free survival of 63%. After propensity-score matching for age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage, and serum albumin, tafamidis was significantly associated with lower all-cause mortality (hazard ratio [HR] 0.28; 95%-confidence interval [CI] 0.13–0.61; P = .001) and fewer composite events (HR 0.56; 95%-CI 0.33–0.97; P = .039). In tafamidis-treated patients, primary and secondary endpoints were associated with advanced NAC stage (P < .031; P < .009), age ≥80 years (P = .022; P = .004), and serum albumin ≤42.5 g/L (P = .015; P < .001), whereas NYHA class ≥III predicted only the composite endpoint (P = .059; P < .001). Conclusions: This study provides long-term real-world outcome data for ATTR-CM patients treated with tafamidis based on physician clinical judgement. Adverse outcomes were strongly predicted by low serum albumin, advanced NAC stage, and older age, emphasizing the importance of early diagnosis and timely therapy of ATTR-CM.Keywords
Funding Information
- University of Würzburg and Tomtec Imaging Systems
- Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie (MED-1811-0011)
- Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie (LSM-2104-0002)
- Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie (LSM-2403-0005)
- Cardio-immune interfaces (453989101)
- Medizinische Fakultät, Universität Duisburg-Essen
- Deutsche Forschungsgemeinschaft (517043330)
This publication has 30 references indexed in Scilit:
- Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational StudyESC Heart Failure, 2024
- Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Journal of Cardiac Failure, 2024
- Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid CardiomyopathyESC Heart Failure, 2023
- Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT TrialEuropean Journal of Heart Failure, 2023
- Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart FailureCurrent Problems in Cardiology, 2023
- Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018Clinical Research in Cardiology, 2022
- Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysisEuropean Journal of Heart Failure, 2022
- Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service PopulationThe American Journal of Cardiology, 2022
- Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awarenessHeart Failure Reviews, 2021
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011